Early detection of lung cancer through analysis of VOC biomarkers in exhaled breath: The LuCID study
| Autor: | Marc P. C. van der Schee, Jasper Boschmans, Rob Smith, Russell Parris, Billy Boyle, Duncan Apthorp, Simon Kitchen, Robert C Rintoul, The LuCID Consortium |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
education.field_of_study business.industry Population Late stage Early detection Cancer medicine.disease Lucid dream 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Internal medicine Medicine 030212 general & internal medicine Stage (cooking) business Lung cancer education Lung cancer screening |
| Zdroj: | Lung Cancer. |
| DOI: | 10.1183/1393003.congress-2017.oa1472 |
| Popis: | Introduction: Currently almost 70% of lung cancer patients are diagnosed at late stage when curative treatment is rarely achievable. There is an urgent need for better early detection methods. Changes in cellular activity underlying cancer growth are reflected by cellular metabolites. The LuCID study aims to use the exhaled fraction of these metabolite, volatile organic compounds (VOCs), as non-invasive breath biomarkers for early detection of lung cancer. Methods: LuCID is a multi-centre study (ClinicalTrials.gov ID NCT02612532) evaluating breath VOCs in patients with a clinical suspicion of lung cancer. Using tidal breathing, patients breathe into the ReCIVA Breath Sampler for 7 minutes to collect bronchial enriched and end-tidal breath fractions on stable sorbent tubes for later analysis by GC-MS and Field Asymmetric Ion Mobility Spectrometry (FAIMS, Owlstone Medical Ltd). A classification algorithm will be constructed from chemical spectral data, and undergo internal and external blinded validation to provide a ROC-curve detailing diagnostic accuracy. Results: The LuCID study has recruited 691 patients to date from 21 centres (mean age 67, SD 12.3). In the current population 38% of these patients have lung cancer (of those with lung cancer: 45% early stage 1a-2b, 55% late stage 3a-4). We will present protocol details and baseline data at the ERS meeting. Based on interim results the LuCID study will recruit up to 3000 patients. Conclusions: The LuCID study is evaluating analysis of exhaled biomarkers as a new modality for lung cancer screening. This non-invasive easy to implement test could drastically improve early detection rates reducing lung cancer morbidity and mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|